## Sam S Yoon

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4805385/publications.pdf

Version: 2024-02-01

87 papers 4,408 citations

34 h-index 106344 65 g-index

88 all docs 88 docs citations

88 times ranked 7080 citing authors

#	Article	IF	CITATIONS
1	Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2360.	7.4	394
2	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 2016, 34, 460-468.	1.6	363
3	A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine, 2007, 13, 992-997.	30.7	274
4	Diagnosis, Management, and Outcomes of 115 Patients with Hepatic Hemangioma. Journal of the American College of Surgeons, 2003, 197, 392-402.	0.5	195
5	Comparison of a Lymph Node Ratio–Based Staging System With the 7th AJCC System for Gastric Cancer. Annals of Surgery, 2012, 255, 478-485.	4.2	175
6	CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance. Clinical Cancer Research, 2014, 20, 3974-3988.	7.0	159
7	Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors. Clinical Cancer Research, 2008, 14, 1529-1539.	7.0	157
8	Analysis of Hypoxia-Related Gene Expression in Sarcomas and Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth Factor A. Cancer Research, 2005, 65, 5881-5889.	0.9	134
9	Targeted Deletion of the Calcineurin Inhibitor DSCR1 Suppresses Tumor Growth. Cancer Cell, 2008, 13, 420-431.	16.8	121
10	Prognostic Factors and Outcomes of Patients with Myxofibrosarcoma. Annals of Surgical Oncology, 2013, 20, 80-86.	1.5	105
11	Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases. Oncologist, 1999, 4, 197-208.	3.7	104
12	Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Annals of Surgery, 2018, 267, 105-113.	4.2	103
13	The Diminishing Role of Surgery in the Treatment of Gastric Lymphoma. Annals of Surgery, 2004, 240, 28-37.	4.2	98
14	Proton-Beam, Intensity-Modulated, and/or Intraoperative Electron Radiation Therapy Combined with Aggressive Anterior Surgical Resection for Retroperitoneal Sarcomas. Annals of Surgical Oncology, 2010, 17, 1515-1529.	1.5	97
15	Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3402-11.	7.1	90
16	Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. Clinical Cancer Research, 2016, 22, 971-983.	7.0	89
17	Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1081-1090.	0.8	77
18	Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. Molecular Cancer Research, 2017, 15, 1106-1116.	3.4	74

#	Article	IF	CITATIONS
19	Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage. Molecular Cancer Therapeutics, 2013, 12, 2591-2600.	4.1	71
20	Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma. PLoS ONE, 2009, 4, e8075.	2.5	71
21	<i>KMT2C</i> Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2018, 24, 6556-6569.	7.0	70
22	Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery, 2011, 149, 347-355.	1.9	64
23	Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Preand Post-imatinib Eras. Annals of Surgery, 2021, 273, 128-138.	4.2	62
24	Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2006, 13, 353-362.	1.5	59
25	Angiogenic Profile of Soft Tissue Sarcomas Based on Analysis of Circulating Factors and Microarray Gene Expression. Journal of Surgical Research, 2006, 135, 282-290.	1.6	57
26	Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Advances in Radiation Oncology, $2017$ , $2$ , $85-93$ .	1.2	57
27	Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression. Cancer Research, 2017, 77, 5349-5359.	0.9	56
28	Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer. Gastric Cancer, 2015, 18, 33-42.	5.3	55
29	Resection of recurrent ovarian or fallopian tube carcinoma involving the liverâ <sup>†</sup> . Gynecologic Oncology, 2003, 91, 383-388.	1.4	51
30	Lymphadenectomy for Gastric Adenocarcinoma: Should West Meet East?. Oncologist, 2009, 14, 871-882.	3.7	51
31	Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis. Cell Metabolism, 2020, 31, 174-188.e7.	16.2	51
32	CD44s expression in human colon carcinomas influences growth of liver metastases. International Journal of Cancer, 2000, 85, 523-526.	5.1	48
33	Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft-Tissue Sarcoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1207-1216.	0.8	40
34	PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas. Oncogenesis, 2021, 10, 12.	4.9	38
35	Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxiaâ€inducible factor 1α. International Journal of Cancer, 2013, 132, 29-41.	5.1	35
36	Indications for Total Gastrectomy in <i>CDH1</i> Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surgery, 2020, 155, 1050.	4.3	34

#	Article	IF	Citations
37	KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem–Like Cells and Promotes Metastasis. Molecular Cancer Research, 2019, 17, 1945-1957.	3.4	31
38	Extended Lymphadenectomy in Gastric Cancer Is Debatable. World Journal of Surgery, 2013, 37, 1773-1777.	1.6	30
39	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. Annals of Surgical Oncology, 2014, 21, 1130-1137.	1.5	29
40	Noncurative Gastrectomy for Gastric Adenocarcinoma Should only be Performed in Highly Selected Patients. Annals of Surgical Oncology, 2013, 20, 3512-3518.	1.5	28
41	Platelet-derived growth factor receptor- $\hat{l}\pm$ and $-\hat{l}^2$ promote cancer stem cell phenotypes in sarcomas. Oncogenesis, 2018, 7, 47.	4.9	28
42	Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1508-1515.	1.5	26
43	D2 Lymphadenectomy with Surgical Ex Vivo Dissection into Node Stations for Gastric Adenocarcinoma Can Be Performed Safely in Western Patients and Ensures Optimal Staging. Annals of Surgical Oncology, 2013, 20, 2991-2999.	1.5	25
44	Comparison of Young Patients with Gastric Cancer in the United States and China. Annals of Surgical Oncology, 2017, 24, 3964-3971.	1.5	25
45	CDX1 Expression Induced by CagA-Expressing <i>Helicobacter pylori</i> Promotes Gastric Tumorigenesis. Molecular Cancer Research, 2019, 17, 2169-2183.	3.4	25
46	An Active Learning Approach for Rapid Characterization of Endothelial Cells in Human Tumors. PLoS ONE, 2014, 9, e90495.	2.5	24
47	Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer. Practical Radiation Oncology, 2013, 3, e11-e19.	2.1	23
48	Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. Practical Radiation Oncology, 2014, 4, 167-173.	2.1	22
49	Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield. Journal of Gastrointestinal Surgery, 2016, 20, 165-171.	1.7	22
50	Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling. Oncogene, 2021, 40, 922-936.	5.9	20
51	Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials. Current Angiogenesis, 2012, 1, 169-179.	0.1	19
52	Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF- $11\pm$ inhibition, and hypoxia-activated chemotherapy. Oncotarget, 2016, 7, 42844-42858.	1.8	18
53	PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance. Cell Death and Disease, 2021, 12, 749.	6.3	16
54	Surgical placement of biologic mesh spacers prior to external beam radiation for retroperitoneal and pelvic tumors. Practical Radiation Oncology, 2013, 3, 199-208.	2.1	15

#	Article	IF	CITATIONS
55	Surveillance Endoscopy in the Management of Hereditary Diffuse Gastric Cancer Syndrome. Clinical Gastroenterology and Hepatology, 2021, 19, 189-191.	4.4	15
56	The New American Joint Commission on Cancer Staging System for Soft Tissue Sarcomas: Splitting versus Lumping. Annals of Surgical Oncology, 2018, 25, 1101-1102.	1.5	14
57	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. Annals of Surgical Oncology, 2021, 28, 4829-4838.	1.5	14
58	Surgical management of retroperitoneal and pelvic sarcomas. Journal of Surgical Oncology, 2015, 111, 553-561.	1.7	13
59	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
60	Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma. Annals of Surgery, 2021, 273, 1189-1196.	4.2	11
61	Decreased length of stay and earlier oral feeding associated with standardized postoperative clinical care for total gastrectomies at a cancer center. Surgery, 2016, 160, 607-612.	1.9	10
62	Long-Term Survival after Minimally Invasive Versus Open Gastrectomy for Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of Patients in the United States and China. Annals of Surgical Oncology, 2020, 27, 802-811.	1.5	10
63	CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer. British Journal of Cancer, 2020, 123, 1131-1144.	6.4	10
64	Linear-Stapled Side-to-Side Esophagojejunostomy with Hand-Sewn Closure of the Common Enterotomy After Prophylactic and Therapeutic Total Gastrectomy. Journal of Gastrointestinal Surgery, 2017, 21, 712-722.	1.7	8
65	Adult primary retroperitoneal teratoma. Surgery, 2005, 137, 663-664.	1.9	7
66	Laparoscopic Versus Open Surgery for Gastric Adenocarcinoma. Annals of Surgery, 2016, 264, 223-225.	4.2	7
67	Performance of the American College of Surgeons NSQIP Surgical Risk Calculator for Total Gastrectomy. Journal of the American College of Surgeons, 2020, 231, 650-656.	0.5	7
68	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 828-837.	1.4	6
69	Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 4238-4246.	1.5	6
70	Comparison of Outcomes for Elderly Gastric Cancer Patients at Least 80 Years of Age Following Gastrectomy in the United States and China. Annals of Surgical Oncology, 2018, 25, 3629-3638.	1.5	6
71	Increased CD44 Expression and MEK Activity Predict Worse Prognosis in Gastric Adenocarcinoma Patients Undergoing Gastrectomy. Journal of Gastrointestinal Surgery, 2021, 25, 1147-1155.	1.7	6
72	MDCT imaging of Alloderm biologic mesh spacers in the abdomen and pelvis â€" preliminary experience. Clinical Imaging, 2014, 38, 279-282.	1.5	5

#	Article	IF	CITATIONS
73	Treatment for local control of retroperitoneal and pelvis sarcomas: A review of the literature. Surgical Oncology, 2022, 43, 101814.	1.6	5
74	FOXC1 modulates stem-like cell properties and chemoresistance through Hedgehog and EMT signaling in gastric adenocarcinoma. Molecular Therapy, 2021, , .	8.2	4
75	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
76	Extent of gastrectomy and lymphadenectomy for gastric adenocarcinoma. Surgical Oncology, 2022, 40, 101689.	1.6	3
77	Open and minimally invasive gastrectomy in Eastern and Western patient populations: A review of the literature and reasons for differences in outcomes. Journal of Surgical Oncology, 2022, 126, 279-291.	1.7	3
78	Varying Lymphadenectomies for Gastric Adenocarcinoma in the East Compared with the West: Effect on Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 250-255.	3.8	2
79	ASO Visual Abstract: Association of Obesity with Worse Operative and Oncologic Outcomes Among Patients Undergoing Gastric Cancer Resection. Annals of Surgical Oncology, 2021, 28, 410-411.	1.5	1
80	CD44s expression in human colon carcinomas influences growth of liver metastases. , 2000, 85, 523.		1
81	Abstract 4680: KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem-like cells and promotes metastasis. , 2019, , .		1
82	Abstract 4680: KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem-like cells and promotes metastasis. , 2019, , .		1
83	ASO Author Reflections: Minimally Invasive Surgery for Gastric Cancer—Has the Future Arrived?. Annals of Surgical Oncology, 2020, 27, 744-745.	1.5	0
84	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. Annals of Surgical Oncology, 2021, 28, 7040-7050.	1.5	0
85	Radiation Therapy in Primary Soft Tissue Sarcoma of the Superficial Trunk. Annals of Surgical Oncology, 2021, , 1.	1.5	0
86	Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year follow-up study Journal of Clinical Oncology, 2012, 30, 10058-10058.	1.6	0
87	Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study Journal of Clinical Oncology, 2013, 31, 10520-10520.	1.6	0